This week, we will discuss another target trial emulation study. The FDA says to stop metformin at a GFR of 30. Are they right?
This week, we will discuss the first iteration of KDIGO’s 2025 guidelines on ADPKD. These guidelines are a result of a decade of global collaboration between physicians, researchers, advocates, and patients. The guidelines incorporate ADPKD-specific care as well as many general CKD management practice points.
This week, we will celebrate in advance World Kidney Day by discussing the results of OBInutuzumab in active lupus nephritis. The LUNAR trial (rituximab versus placebo) was “almost” positive, but not quite there. Would Obi overpower its cousin ritux? ✨
This week, we will continue with February’s aldosterone leitmotif: do mineralocorticoid receptor antagonists (MRAs) truly blind the diagnostic in unilateral hypraldosteronism? Is this the article the mythbuster? Draw your own conclusions
This instalment of #TenTweetNephJC - the quickest way to stay up to date - recaps the recent NephJC chat on a mechanistic study investigating diuretic resistance, check it out at the link….
This one is a difficult one. And Sophia Ambruso had created a nice one for NephMadness - so why mess with such a nice piece of work? Here it is:
The PATH-BP trial dropped - check out the results and the take from the #NephJC chats (in an <2 min summary)
Excellent visual abstract from Husam Alzayer, NSMC intern of the class of 2022
